August 5, 2022
Adagrasib in Previously Treated Patients With KRAS G12C–Mutated Advanced NSCLC BookmarkGeorge Lundberg, MD
As reported by The ASCO Post, the drug adagrasib has shown some promising results in a clinical trial for people with advanced non-small cell lung cancer (NSCLC) with a KRAS-g12c mutation whose cancer progressed after prior treatment. The U.S. Food and Drug Administration (FDA) allows adagrasib to be given to people whose cancer has a KRAS-g12c mutation through expanded access.
June 2, 2022
Kaumudi Bhawe, PhD
At Cancer Commons, we don’t just help people navigate cancer treatment; we learn from everyone we help. Here, our Curious Dr. George asks Cancer Commons Clinical Scientist Kaumudi Bhawe, PhD, to share how new knowledge can be captured from every patient to help many more. Curious Dr. George: Cancer Commons has accumulated in-depth data on many hundreds of patients with various cancers. Because of the… Read more »
July 28, 2021
FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy BookmarkGeorge Lundberg, MD
On May 28, 2021, the U.S. Food and Drug Administration granted Accelerated Approval for Lumakras (sotorasib), the first targeted therapy for cancer with a mutation in the KRAS gene.
March 9, 2021
A new cancer diagnosis is overwhelming. Patients often ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks lung cancer expert Howard (Jack) West, MD, how he would handle his own diagnosis of advanced lung cancer. Dr. West is a Princeton- and Harvard-educated oncologist with additional training and experience in Boston and Seattle focusing on lung cancer.… Read more »
October 16, 2020
Molecular Profiling in Metastatic Colorectal Cancer BookmarkGeorge Lundberg, MD
Article from the academic journal Oncology, curated by Contributing Editor George Lundberg, MD, who notes:
Molecular testing is essential to guide effective treatment in metastatic colorectal cancer. This academic review article provides a good overview of the topic.
January 10, 2020
Using Real World Evidence to Show Initial Results of a Drug Combination in Pancreatic Cancer PatientsLola Rahib, PhD
In collaboration with xCures and the Huntsman Cancer Institute at the University of Utah, Cancer Commons presented initial findings from our real-world data registry on a novel treatment combination for pancreatic cancer patients at a conference in San Diego, CA, today. The “Special Conference on Advancing Precision Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies” is hosted by the… Read more »
March 6, 2019
Cancer Commons and xCures Invite Participation from Patients Who Try New Combo Therapy for Pancreatic Cancer
Treatment for metastatic pancreatic cancer has seen progress in recent years, but outcomes remain poor and treatment advances that can prolong patients’ lives, even for a few months, are eagerly awaited. Two papers published today in the scientific journal Nature Medicine report that a new combination of two drugs that are FDA-approved for other conditions may significantly delay progression of pancreatic cancer in cells… Read more »
May 31, 2017
Emma Shtivelman, PhD
Mutations in the gene that encodes the KRAS protein are frequently encountered in various human cancers. They are found in about 30% of non-small cell lung cancers (NSCLCs), making KRAS the single most common gene mutated in this cancer. The rate of KRAS mutations in other cancers, such as pancreatic or colorectal, is even higher. A mutant KRAS protein that is always in the… Read more »